Corona Remedies fires up EU-GMP hormone plant, adds 20% capacity
The new Ahmedabad facility, spanning 1 lakh sq ft, targets regulated export markets with 194M tablets/capsules annual capacity, turning a regulatory milestone into revenue generation.
What's new
- Commercial production begins at EU-GMP approved Women's Hormone facility in Bhayla, Ahmedabad.
- Annual capacity: 194M tablets/capsules and 1.5M ointments/gels.
- In-house hormone capacity rises nearly 20%, boosting export and domestic reach.
Why this matters
The plant converts a previously disclosed EU-GMP certification into a revenue-generating asset. For a mid-cap pharma with trailing revenue growth of 20% and PAT growth of 44%, dedicated hormone capacity for regulated export markets is a material growth lever.
What we're watching
- Revenue contribution from the new plant in coming quarters.
- Securing of export contracts for complex hormone therapies.
- Margin improvement from higher-value product mix.
The full read
Corona Remedies just switched on its EU-GMP Women's Hormone plant in Ahmedabad. Hardly routine. The 1 lakh sq ft facility adds nearly 20% to in-house hormone capacity, producing 194 million tablets/capsules and 1.5 million ointments/gels annually—enough to target regulated export markets. This converts a previously disclosed regulatory milestone into a tangible revenue contributor. For a mid-cap pharma with trailing revenue growth of 20% and PAT growth of 44%, the dedicated hormone capacity is a material growth lever, even if the exact revenue impact remains unguided.
Questions answered
- What is the significance of EU-GMP approval for this plant?
- EU-GMP certification allows Corona Remedies to export to regulated European markets, which typically command higher margins and volumes. The plant is designed for multiple hormone dosage forms, making it versatile for both domestic and export needs.
- How does this facility change Corona's product mix?
- The plant adds dedicated capacity for women's hormone therapies—tablets, soft gel capsules, ointments, and gels. This expands Corona's portfolio into a specialised, high-demand therapeutic area.
- What was Corona's prior hormone capacity?
- The exact prior capacity is not disclosed, but the new plant adds nearly 20% to in-house hormone manufacturing capacity, implying a meaningful expansion relative to existing operations.
- Will the new capacity be fully utilised soon?
- The filing does not provide utilisation targets. Ramp-up will depend on order wins and regulatory clearances in target export markets.
- How does this align with Corona's export strategy?
- The facility's EU-GMP compliance directly supports exports to regulated markets. Corona already has a domestic presence; the new plant positions it to capture export demand for complex hormone therapies.